Airtame Launches Airtame Cloud, Signaling New Focus on Combined Hardware and Software Offering
15.1.2020 16:00:00 EET | Business Wire | Press release
Airtame, the leading wireless screen sharing and collaboration platform, today announced the official launch of Airtame Cloud, a new software-as-a-service product designed to make screens smarter. The open platform offers device management and access to a range of digital signage solutions, helping users create smarter offices, workplaces and schools with their screens.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200115005060/en/
Airtame Cloud (Graphic: Business Wire)
Airtame Cloud -- which has been available in beta for over a year, and is already used by 6,500 organizations globally -- is a unified platform that enables users to manage and update their screens remotely. It was built on an open ecosystem that seamlessly integrates with a range of applications that can be used to create tailored digital signage, such as Google Slides, Microsoft OneDrive, Trello, Dropbox, and YouTube, with more integrations to come.
Cloud will allow users to:
- Manage screens remotely, freeing up IT administrators to change settings and conduct bulk updates with cloud access to Airtame-enabled screens
- Boost productivity and engagement, with personalized digital signage in meeting rooms, classrooms and common areas
- Save on power, by scheduling screens to turn on and off according to office or school hours
- Avoid blank screens, by scheduling imagery and videos to play on loop
The launch of Cloud marks the evolution of Airtame as it continues to grow from a hardware to solution-centric business, with a strong focus on facilitating smart offices and schools around the world.
“With Airtame Cloud, we’re providing a solution that empowers our customers to boost engagement and productivity for employees, students and visitors, whether that be in the office, meeting room or classroom,” said Airtame Co-Founder and Co-CEO Jonas Gyalokay.
“Part of our vision at Airtame is to help enterprises and schools create smarter offices and classrooms. While this starts with screens, we imagine one day it could extend to all aspects of the workplace or classroom, with the potential to automate lighting, sound, room temperature and more.
“With the evolution of IoT, the possibilities to connect devices and screens are endless. As a starting point, Airtame Cloud will help schools and enterprises reduce their energy consumption by automating screens to turn off when they’re not being used. We’re looking forward to embracing technology to build additional hardware and software features of this kind in the future.”
Airtame Cloud will launch with two plans: Airtame Cloud Lite, a free version of the product that offers the essential features needed to manage and update Airtame devices, and Airtame Cloud Plus, a premium version that enables digital signage and additional features needed to create a smart office or classroom.
The launch follows a series of important milestones for Airtame, including the recent announcement of its industry-first partnership with Airserver. The company has enjoyed 100% YoY growth since its market launch in 2014.
ENDS
Access the full press kit containing imagery and video materials here.
ABOUT AIRTAME:
Airtame offers a wireless screen sharing and collaboration platform that allows users to instantly display content from any personal device to any shared screen. The platform is used to promote interactivity and collaboration in meetings, presentations and classroom settings, as well as for digital signage in retail stores, corporate environments, conference facilities, hotels, and other venues. Airtame was launched in 2014 and has grown into a company with 100+ people, and with offices in New York, Los Angeles, Copenhagen, and Budapest.
To learn more, visit www.airtame.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200115005060/en/
Contact information
Martin Stockfleth Larsen
Airtame
+45 31 661 663
martin.larsen@airtame.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 09:07:00 EET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 09:00:00 EET | Press release
Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers across Europe to bring advanced proton treatment to their patients. “With both FDA clearance and CE Marking now in hand, the MEVION S250-FIT is
Bureau Veritas: Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 08:30:00 EET | Press release
Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2024, › Free Cash Flow of EUR 824.2 million, up 3.9% organically and up 2.6% at constant currency, and cash conversion of 107%2, › Adjusted net
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 08:00:00 EET | Press release
Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat in a mouse model in Sandhoff disease, a form of GM2 gangliosidosis with no approved treatments—alongside healthy control subjects. The research assessed how the drug’s exposure relates to its effects in the brain, demonstrating a significant increase in both survival (22%; 26 days) and assessments of movement and behavior at 16 weeks versus un
Galderma Announces Triple Approval of New State-of-the-Art Restylane ® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 08:00:00 EET | Press release
Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-art syringe for use with its NASHA® lidocaine range of Restylane products in multiple facial indications including the cheeks, nose, chin, jawline, tear troughs, nasolabial folds, marionette lines, as well as in the hands.1-3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224651688/en/ The syringe features a next-generation ergonomic design that enhances precision and control; includes an optimized syringe-needle connection with the new Terumo K-Pack Enhance™ needle; and offers a premium color-coded packaging and syringe design to support easy range navigation for practitioners.4-7, 9,10 It sets a new standard in Injectable Aesthetic devices and demonstrates Galderma’s unwavering commitment to driving innovation to meet the needs of both practitioners and patients. “Developing this new syringe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom